PET imaging to identify heart amyloidosis with new marker
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study uses a new imaging technique (PET scan with a tracer called evuzamitide) to detect a type of heart disease called cardiac amyloidosis in patients whose standard heart scans were unclear but who have elevated levels of a new blood marker (TAD1). The goal is to find a better way to diagnose this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have heart failure or are a carrier of TTR gene changes without symptoms yet
- Your standard nuclear heart scan was unclear (not diagnostic) for amyloidosis
- Your TAD1 blood test shows elevated levels
- You don't have signs of AL or AA amyloidosis (checked by specific blood tests)
- You can provide written informed consent and follow all study visits and instructions
- You are not pregnant, not breastfeeding, and not on certain blood thinners like heparin
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of imaging scan ([64Cu]FBP8 PET) to detect blood clots that may form in the heart's left atrial appendage (a small pouch in the heart) in patients with amyloid cardiomyopathy (a disease where abnormal protein builds up in heart muscle) who also have irregular heartbeat. The scan may help doctors catch clots earlier and prevent strokes.
This study tests a new PET imaging tracer called [18F]FT8 to see if it can better detect amyloid protein buildup in the heart. It may help doctors diagnose and monitor cardiac amyloidosis more accurately.
This trial is testing a special PET/CT scan (Pan-Amyloid) that finds abnormal protein deposits (amyloid) in the heart and body. It is for people who have or may have cardiac amyloidosis and are already planning to get this scan.
This study uses a special PET scan tracer to see how consistent the images are in people with heart amyloidosis (a buildup of abnormal protein in the heart) and in people without the condition. The goal is to improve diagnosis and monitoring.
This study looks at how a type of heart condition called transthyretin cardiac amyloidosis changes over time, using a special imaging test called a bone scan. The goal is to see if the scan can help track the disease and potentially improve care.
This study uses a hybrid PET/MRI scanner to take detailed images of the heart in people with amyloidosis. The goal is to see how well this scan shows the buildup of amyloid protein, which could help doctors better diagnose and manage the condition.
Hear when a new Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.